AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Lipid profiles of nonwhites, whites benefit equally from raloxifene: posthoc analysis of 7,705 women.(Gynecology)
MIAMI BEACH -- Raloxifene improves the lipid profiles as well in nonwhite women as in white women, according to data extracted from a posthoc analysis of the Multiple Outcomes of Raloxifene Evaluation.
Women with the highest baseline cardiovascular risk benefited the most from raloxifene. After 4 years of therapy, they experienced a 40% decrease in their baseline risk of heart attack or stroke, Dr. Susan Johnson commented at the annual meeting of the North American Menopause Society.
The MORE trial randomized 7,705 postmenopausal women with osteoporosis to placebo or raloxifene (Evista) in doses of 60 mg/day or 120 mg/day. The posthoc subgroup analysis included 219 nonwhite women, of whom 55% were Hispanic, 21% were Southeast Asian, 10% were black, 5% were West Asian, and 9% classified as other.
Lipid profile and cardiovascular risk improvements in this group mirrored those seen in white women, said Dr. Johnson of the University of Iowa, Iowa City.
Baseline lipid levels were similar in the placebo and raloxifene groups, but women in the placebo group were slightly ...
- Raloxifene tx not linked to gallbladder disease: posthoc analysis of major...
- Magazine article from: OB GYN News Sullivan, Michele G. November 1, 2003 700+ words
...5% in the placebo group vs. 2.6% in the raloxifene groups. About 2...12% in the placebo group and 13% in the raloxifene groups reported worsening...1% in the raloxifene groups and 1.4% in the placebo group. MORE was...
- Cognitive Function in Postmenopausal Women Treated with Raloxifene.
- Magazine article from: OB/GYN Clinical Alert June 1, 2001 700+ words
...3 treatment groups on any of the cognitive tests at baseline or after 3 years. More women in the raloxifene groups than in the placebo group reported new or worsened hot flashes, but there was no correlation between presence or absence of...
- Biovail Parkinson's drug disappoints; U.S. partner's shares plunge as placebo...
- Newspaper article from: The Toronto Star (Toronto, Ontario) September 2, 2009 700+ words
...tolerate the drug but neither group had a statistically better outcome than the placebo group. All three groups experienced some improvement - including the placebo group, which wasn't expected, the companies said. Biovail shares closed down...
- Estrogen therapy more effective for increasing bone density than raloxifene.
- Newspaper article from: Biotech Week May 12, 2004 700+ words
...declined by 2% in the placebo group, was stable in the two raloxifene groups, and increased by 4...of the study for the placebo group and the CEE group; however...greater change than in the raloxifene groups, which respectively...
- Journal of Urology Article Reports MacroChem Drug Induced Erection in 67-75% of...
- Press release article from: PR Newswire August 26, 1999 700+ words
LEXINGTON, Mass., Aug. 26 /PRNewswire/ -- Investigators from Northwestern University Medical School have reported in the September 1999 Journal of Urology that Topiglan(TM), a topical drug under development by MacroChem Corporation (Nasdaq: MCHM), induced erection in 67 to 75 percent of impotent
- Novel agent eases acute heart failure symptoms: dyspnea was improved in 53% of...
- Magazine article from: Family Practice News Jancin, Bruce July 1, 2008 700+ words
CHICAGO -- It's full speed ahead for a pivotal phase III clinical trial of the novel drug rolofylline in patients with acute decompensated heart failure and renal dysfunction, on the basis of its impressive performance in a 301-patient pilot study. In the preliminary round, the selective adenosine
- Final Data from Eli Lilly and Company's Landmark MORE Study Show Evista...
- Press release article from: Business Wire February 13, 2001 700+ words
...confirmed in the placebo group of 2,576 women...cancer among the raloxifene groups compared with placebo...confirmed in the placebo group, compared with 10...cancers in the combined raloxifene groups. This resulted in...
- Coming soon to a pharmacy near you - designer estrogens. (includes related...
- Newspaper article from: HealthFacts January 1, 1998 700+ words
...density in the lumbar spine and the hip, whereas, the placebo group lost about that amount. Investigators call this a significant...of vaginal bleeding was identical in the placebo and the raloxifene groups. As for raloxifenes purported lack of cancer-causing...
